Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQM48O
|
|||
| Drug Name |
RO7121661
|
|||
| Synonyms |
RG7769
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Esophageal squamous cell carcinoma [ICD-11: 2E60.1; ICD-10: D00.1; ICD-9: 150] | Phase 2 | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis A virus cellular receptor 2 (TIM3) | Target Info | Inhibitor | [2] |
| Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04785820) A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus. U.S. National Institutes of Health. | |||
| REF 2 | Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.